Entering text into the input field will update the search result below

Trovagene up 16% premarket on positive onvansertib data

Apr. 05, 2019 8:30 AM ETCardiff Oncology, Inc. (CRDF) StockBy: Douglas W. House, SA News Editor
  • Nano cap Trovagene (TROV) is up 16% premarket on light volume in reaction to updated results from its ongoing open-label Phase 1b/2 clinical trial evaluating onvansertib, combined with standard-of-care chemo, in patients with acute myeloid leukemia (AML).
  • The company says the best results have been observed in the onvansertib + decitabine arm where 50% (n=3/6) of evaluable patients receiving the two highest doses to date achieved complete responses.
  • According to ClinicalTrials.gov, the estimated primary completion date is January 2020.

Recommended For You

More Trending News

About CRDF Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CRDF--
Cardiff Oncology, Inc.